NTDT
-
News
EXCLUSIVE WEBINAR | Guidelines for the Management of Non-Transfusion Dependent β-Thalassaemia
📌 Webinar Title: Guidelines for the Management of Non-Transfusion Dependent β-Thalassaemia 📌 Date & Time: Friday, February 02, 2024, 15:00 CET Recognizing the Clinical Relevance of NTDT Non‐transfusion‐dependent thalassaemias…
Read More » -
News
THAL PALS PODCAST | New Episode on TIF’s NTDT Guidelines Out Now
Dr. Κevin Kuo, MD, MSc, Clinician Investigator, and Μrs. Laurice Levine, Thalassaemia Patient Advocate, talk to TIF’s Executive Director, Dr Androulla Eleftheriou, and Dr. Khaled Musallam, Chief Research Officer, MD,…
Read More » -
TIF News
NEW PUBLICATION | Guidelines for the Management of Non-Transfusion-Dependent β-Thalassaemia
This novel edition is an invaluable contribution in upgrading the care of individuals with NTDT, a condition that has been underestimated in importance and clinical significance for many years. TIF…
Read More » -
Clinical News
TOP STORY | EU Approves Luspatercept for Anemia in Patients with Non–Transfusion-Dependent β-Thalassaemia
The approval was based on findings from the phase 2 BEYOND trial, which demonstrated that 77.1% of patients treated with luspatercept (n = 74/96) experienced a mean haemoglobin (Hb) increase…
Read More » -
News
FDA Grants Priority Review to Luspatercept-aamt for Anemia in Adults With NTD β-Thalassaemia
The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 27, 2022. In addition, the European Medicines Agency (EMA) has validated the Type II variation…
Read More » -
News
MITAPIVAT | FDA Grants Priority Review To New Drug For Pyruvate Kinase Deficiency
The NDA was granted a Priority Review designation and has been given a Prescription Drug User Fee Act (PDUFA) action date of February 17, 2022, accelerating the review time from…
Read More »